Actinium Highlights Foundational Patents Covering the Composition of Apamistamab Antibody and Iomab-B Antibody Radiation Conjugate for Targeted…
By daniellenierenberg
NEW YORK, Nov. 23, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today highlighted its intellectual property portfolio for apamistamab, a CD45 targeting antibody, and the Antibody Radiation Conjugate (ARC) comprised of apamistamab and the radioisotope iodine-131 used in the Company's lead Phase 3 candidate, Iomab-B, and its Iomab-ACT programs. Actinium owns issued or pending patents within the United States and globally covering composition of matter, formulation, methods of use, and methods of administration with potential coverage for 19 years or longer. Importantly, Actinium owns an issued patent in the US covering composition of matter, for which the Company expects validity until 2037.In addition, the Company owns a second issued US patent that further covers composition of matter, methods of use, and methods of administration for Iomab-B. The company has also received a notice of allowance in Europe for this second patent and expects it to be in force until 2036.
Iomab-B is currently being investigated in the ongoing pivotal Phase 3 SIERRA trial, which is over 75% enrolled, for targeted conditioning prior to potentially curative bone marrow transplant (BMT) for patients with relapsed or refractory Acute Myeloid Leukemia ("R/R AML"). In addition, Actinium is utilizing apamistamab with lower doses of iodine-131, known as Iomab-ACT, for targeted conditioning prior to gene therapy and adoptive cell therapy ("ACT"), namely CAR-T, including in its recently announced collaboration with Memorial Sloan Kettering Cancer Center that is supported by NIH STTR Fast Track grant funding.
"The continued protection of our lead asset Iomab-B, our Iomab-ACT program and apamistamab by a strong patent position is an important component of our development efforts, particularly as we approach the conclusion of our pivotal Phase 3 SIERRA trial for BMT conditioning in R/R AML The growth of BMT, ACT and Gene Therapy has highlighted the importance of conditioning and the need to move beyond non-targeted chemotherapy to increase the number of patients that could benefit from these potentially curative therapies.CD45 is an ideal target for conditioning applications given its unique expression on blood cancer cells and blood forming stem and immune cells and with no expression outside the hematopoietic or blood system," said Dr. Dale Ludwig, Actinium's Chief Scientific Officer. "Apamistamab is well characterized and its use in conditioning is supported by extensive clinical data across multiple clinical trials and indications. Our robust data shows that apamistamab has a favorable biodistribution profile that, together with our ARC technology, has significant advantages over other approaches such antibody drug conjugates that require payload internalization, making them impractical for targeting CD45.Further, our ARC approach allows us to use varying intensities of targeted radiation to achieve our desired conditioning outcome.With these important patents in place, and continued expansion of our patent portfolio in the US, EU and other select countries, we look forward to continuing to build out our targeted conditioning strategic business unit."
About Iomab-B
Iomab-B is Actinium's lead product candidate that is currently being studied in a 150-patient, multicenter pivotal Phase 3 clinical trial in patients with relapsed or refractory acute myeloid leukemia who are age 55 and above. Upon approval, Iomab-B is intended to prepare and condition patients for a bone marrow transplant, also referred to as a hematopoietic stem cell transplant, which is often considered the only potential cure for patients with certain blood-borne cancers and blood disorders. Iomab-B targets cells that express CD45, a pan-leukocytic antigen widely expressed on white blood cells with the monoclonal antibody, apamistamab (formerly BC8), labeled with the radioisotope, iodine-131. By carrying iodine-131 directly to the bone marrow in a targeted manner, Actinium believes Iomab-B will avoid the side effects of radiation on most healthy tissues while effectively killing the patient's cancer and marrow cells. In a Phase 1/2 clinical study in 68 patients with advanced AML or high-risk myelodysplastic syndrome (MDS) age 50 and older, Iomab-B produced enabled 100% of patients to proceed to transplant with all patients achieving transplant engraftment by day 28. Iomab-B was developed at the Fred Hutchinson Cancer Research Center where it has been studied in almost 300 patients in a number of blood cancer indications, including acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, Hodgkin's disease, Non-Hodgkin lymphomas and multiple myeloma. Actinium obtained the worldwide, exclusive rights to apamistamab (BC8) and Iomab-B from the Fred Hutchinson Cancer Research Center. Iomab-B has been granted Orphan Drug Designation for relapsed or refractory AML in patients 55 and above by the U.S. Food and Drug Administration and the European Medicines Agency.
About Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing ARCs or Antibody Radiation-Conjugates, which combine the targeting ability of antibodies with the cell killing ability of radiation.Actinium's lead application for our ARCs is targeted conditioning, which is intended to selectively deplete a patient's disease or cancer cells and certain immune cells prior to a BMT or Bone Marrow Transplant, Gene Therapy or Adoptive Cell Therapy (ACT) such as CAR-T to enable engraftment of these transplanted cells with minimal toxicities.With our ARC approach, we seek to improve patient outcomes and access to these potentially curative treatments by eliminating or reducing the non-targeted chemotherapy that is used for conditioning in standard practice currently.Our lead product candidate, I-131 apamistamab (Iomab-B) is being studied in the ongoing pivotal Phase 3 Study of Iomab-B in Elderly Relapsed or Refractory Acute Myeloid Leukemia (SIERRA) trial for BMT conditioning.The SIERRA trial is over seventy-five percent enrolled and positive single-agent, feasibility and safety data has been highlighted at ASH, TCT, ASCO and SOHO annual meetings.More information on this Phase 3 clinical trial can be found at sierratrial.com. I-131 apamistamab will also be studied as a targeted conditioning agent in a Phase 1 study with a CD19 CAR T-cell Therapy and Phase 1/2 anti-HIV stem cell gene therapy with UC Davis. In addition, we are developing a multi-disease, multi-target pipeline of clinical-stage ARCs targeting the antigens CD45 and CD33 for targeted conditioning and as a therapeutic either in combination with other therapeutic modalities or as a single agent for patients with a broad range of hematologic malignancies including acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma. Ongoing combination trials include our CD33 alpha ARC, Actimab-A, in combination with the salvage chemotherapy CLAG-M and the Bcl-2 targeted therapy venetoclax. Underpinning our clinical programs is our proprietary AWE (Antibody Warhead Enabling) technology platform.This is where our intellectual property portfolio of over 100 patents, know-how, collective research and expertise in the field are being leveraged to construct and study novel ARCs and ARC combinations to bolster our pipeline for strategic purposes.Our AWE technology platform is currently being utilized in a collaborative research partnership with Astellas Pharma, Inc. Website: https://www.actiniumpharma.com/
Forward-Looking Statements for Actinium Pharmaceuticals, Inc.
This press release may contain projections or other "forward-looking statements" within the meaning of the "safe-harbor" provisions of the private securities litigation reform act of 1995 regarding future events or the future financial performance of the Company which the Company undertakes no obligation to update. These statements are based on management's current expectations and are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with preliminary study results varying from final results, estimates of potential markets for drugs under development, clinical trials, actions by the FDA and other governmental agencies, regulatory clearances, responses to regulatory matters, the market demand for and acceptance of Actinium's products and services, performance of clinical research organizations and other risks detailed from time to time in Actinium's filings with the Securities and Exchange Commission (the "SEC"), including without limitation its most recent annual report on form 10-K, subsequent quarterly reports on Forms 10-Q and Forms 8-K, each as amended and supplemented from time to time.
Contacts:
Investors:Clayton Robertson Actinium Pharmaceuticals, Inc. [emailprotected]
Hans VitzthumLifeSci Advisors, LLC[emailprotected](617) 430-7578
SOURCE Actinium Pharmaceuticals, Inc.
- Comparative analysis of mouse bone marrow and adipose tissue mesenchymal stem cells for critical limb ischemia cell therapy - DocWire News - January 14th, 2021
- Shipyard worker Brad Lawson from Walney may have saved a stranger's life with his stem cell donation - NW Evening Mail - January 14th, 2021
- A Study of Cord Blood Transplantation in Children and Young Adults with Blood Cancers and Non-Cancerous Blood Disorders - On Cancer - Memorial Sloan... - January 14th, 2021
- Adipose Derived Stem Cell Therapy Market Analysis and Forecast, 2020-2026 Coherent Market Insights | BioRestorative Therapies, Inc., Celltex... - January 14th, 2021
- Alterations of NK Cell Phenotype in the Disease Course of Multiple Myeloma - DocWire News - January 14th, 2021
- Bone Therapeutics and Rigenerand sign partnership for cell therapy process development - GlobeNewswire - January 14th, 2021
- Stem Cell Assay Market | Know the aspects that will serve as game-changers for the market - BioSpace - January 14th, 2021
- Companies In The Global G-CSF (Granulocyte Colony Stimulating Factors) Market Are Focusing On Mergers And Acquisitions And Strategic Partnerships To... - January 14th, 2021
- Magenta Therapeutics Highlights Recent Progress and Expected Timing of 2021 Milestones, Including Fo - PharmiWeb.com - January 14th, 2021
- Cate Dyer of StemExpress is Named Businesswoman of the Year! - PRNewswire - January 14th, 2021
- Errant Gene Therapeutics, LLC (EGT) Pushing Clinical Trial of Potentially Curative Treatment for Beta-Thalassemia and Eventually Sickle Cell Disease -... - January 14th, 2021
- Errant Gene Therapeutics, LLC ("EGT") Pushing Clinical Trial of Potentially Curative Treatment for Beta-Thalassemia and Eventually Sickle... - January 14th, 2021
- Information and choices for women and couples at risk of having a baby with sickle cell disease - GOV.UK - January 14th, 2021
- MorphoSys and Incyte Announce Acceptance by Health Canada of the New Drug Submission for Tafasitamab - PharmiWeb.com - January 14th, 2021
- Warm Up with Homemade Broths and Stocks - The Source Weekly - January 14th, 2021
- Gamida Cell to Present Full Data from Phase 3 Study of Omidubicel at TCT, the Combined Transplantation and Cellular Therapy Meetings of ASTCT and... - January 12th, 2021
- Bone Marrow Processing Systems Market Recent developments in the competitive landscape forecast 2018 2025 - SoccerNurds - January 12th, 2021
- Four promising COVID-19 therapies being tested at nearby UVA - Rappahannock News - January 12th, 2021
- Orchard Therapeutics Announces 2021 Corporate Priorities Supporting the Build-out of its Commercial Business in Hematopoietic Stem Cell (HSC) Gene... - January 12th, 2021
- Brave West Lothian women discovers back pain is actually deadly blood cancer - Daily Record - January 12th, 2021
- AGC Biologics Confirms Cell and Gene Therapy Commercial Expertise as Manufacturer of Orchard Therapeutics' Newly Approved Libmeldy(TM) - Daily... - January 5th, 2021
- Stem Cell Therapy Market by Treatment,Application,End Users and Geography Forecast To 2027 - LionLowdown - January 5th, 2021
- MorphoSys and Incyte Announce the Acceptance of the Swissmedic Marketing Authorization Application f - PharmiWeb.com - January 5th, 2021
- Direct Biologics Announces First Patient Treated Under Phase II Expanded Access Protocol Using ExoFlo(TM) to Treat COVID-19 - Tyler Morning Telegraph - January 3rd, 2021
- Lonza's Cocoon will soon make dozens of stem cell therapies all at once - Innovation Origins - January 3rd, 2021
- Bone Marrow Processing Systems Market to Make Great Impact in near Future by -2025 - The Monitor - January 3rd, 2021
- The Myeloproliferative Disorders Drugs Market to grow on an exceptional note in the next 10 years - LionLowdown - January 3rd, 2021
- 2020: The year science took centre-stage - The Hindu - January 3rd, 2021
- Stem cells from cord blood can now be used across many conditions: Mayur Abhaya, MD & CEO, LifeCell Internat.. - ETHealthworld.com - December 28th, 2020
- 'We had to take our health into our hands' - Meet the siblings fighting for their lives with sickle cell disease - South West Londoner - December 28th, 2020
- New class of drugs to treat blood and bone marrow cancers: Research - Hindustan Times - December 26th, 2020
- He got his cheek swabbed at 24. Nothing happened for 14 years. - Las Vegas Review-Journal - December 26th, 2020
- Study clarifies the impact of getting old on hematopoietic stem cells - Microbioz India - December 26th, 2020
- Scientists find new class of drugs that may treat blood, bone marrow cancer - Business Standard - December 26th, 2020
- CAR T-Cell Therapies Are Set to Expand Into More Hematologic Malignancy Indications - Targeted Oncology - December 26th, 2020
- Organ and Tissue Transplantation and Alternatives - GlobeNewswire - December 22nd, 2020
- FDA Resumes eIND Approval for Severe-to-Critical COVID-19 Patients Use of Vyrologix (leronlimab) Following Full Enrollment in CytoDyn's Phase 3 Trial... - December 22nd, 2020
- The 11 most mind-blowing, awe-inspiring health discoveries and innovations of 2020 - Business Insider - Business Insider - December 22nd, 2020
- Orchard Therapeutics Receives EC Approval for Libmeldy for the Treatment of Early-Onset Metachromatic Leukodystrophy (MLD) - GlobeNewswire - December 22nd, 2020
- Comparison of concentrated fresh mononuclear cells and ... - December 21st, 2020
- How Researchers Are Making Do in the Time of COVID-19 - The Wire Science - December 21st, 2020
- Stem Cell or Bone Marrow Transplant Side Effects - December 19th, 2020
- Every Patient Treated With CRISPR Gene Therapy for Blood Diseases Continues to Thrive, More Than a Year On - Good News Network - December 19th, 2020
- Understanding Bone Marrow/Stem Cell Transplant | Knight ... - December 17th, 2020
- Physio Logic Brings Cutting-edge Regenerative Treatments for Sport Injuries and Arthritis to New York City - PRNewswire - December 17th, 2020
- Priming the Immune System to Fight Cancer - PRNewswire - December 17th, 2020
- Creative Medical Technology Stock Price Increased 80.77%: Why It Happened - Pulse 2.0 - December 17th, 2020
- Our View On Orchard Therapeutics - Seeking Alpha - December 17th, 2020
- Hip Preservation With Autologous Osteoblast Cell-Based Treatment in Osteonecrosis of the Femoral Head - Healio - December 17th, 2020
- Research That Saves Lives: Four COVID-19 Therapies Being Tested at UVA - University of Virginia - December 17th, 2020
- Stem Cell Transplant Reduces Relapses and Disability in RRMS... - Multiple Sclerosis News Today - December 16th, 2020
- Creative Medical Technology Holdings Announces Successful Application of ImmCelz Immunotherapy for Treatment of Stroke - PRNewswire - December 16th, 2020
- Novel class of targeted cancer therapies could treat myeloid leukaemias - Drug Target Review - December 16th, 2020
- 1st Patients To Get CRISPR Gene-Editing Treatment Continue To Thrive - NPR - December 16th, 2020
- Bone Regeneration Material Market: Cell-based Segment to Expand Significantly - BioSpace - December 16th, 2020
- Shingles: What triggers this painful, burning rash? - Harvard Health Blog - Harvard Health - December 14th, 2020
- Updated Findings Show Continued Efficacy for CAR T-Cell Therapy in Heavily Pretreated Myeloma - Targeted Oncology - December 14th, 2020
- Early Signs of Activity and Tolerability Found in Allogeneic Product UCART22 for Patients with Relapsed/Refractory CD22+ B-Cell ALL - Cancer Network - December 14th, 2020
- Jasper Therapeutics Announces Data from First Transplant-naive Patient in Phase 1 Clinical Trial of JSP191 as Conditioning Agent in Patients with SCID... - December 13th, 2020
- City of Hope Doctors Present Innovative Therapies to Better Treat Blood Cancers at American Society of Hematology Virtual Conference - Business Wire - December 13th, 2020
- Bid to fund stem cell treatment in Mexico for woman with MS - Bournemouth Echo - December 13th, 2020
- Gamida Cell Provides Pipeline Update, Including Detailed Results of Pivotal Phase 3 Clinical Study of Omidubicel, and Prepares to Start BLA Submission... - December 13th, 2020
- ElevateBio's HighPassBio Presents on Novel T Cell Receptor Cell Therapy for Leukemia Relapse at 62nd Annual ASH Meeting - Business Wire - December 13th, 2020
- Actinium Highlights Iomab-B Safety Data Presented at the 62nd American Society of Hematology Annual Meeting - PRNewswire - December 13th, 2020
- Negrin Shines Light on the Orca-T Story in GVHD - OncLive - December 13th, 2020
- ASH virtual event hears about CRISPR and CAR-T based approaches to hard-to-treat blood disorders and cancers - BioPharma-Reporter.com - December 13th, 2020
- Researchers Trace the Origin of Blood Cancer to Early Childhood, Decades before Diagnosis - PRNewswire - December 13th, 2020
- Haywards Heath woman's bid to fund stem cell treatment to combat MS - Mid Sussex Times - December 13th, 2020
- Magenta Therapeutics Announces Commencement of First Phase 2 Clinical Trial of MGTA-145 for Stem Cell Mobilization, Oral Presentation of MGTA-145... - December 13th, 2020
- Antileukemic Activity Seen With Flotetuzumab in Primary Induction Failure, Early-Relapse AML - Hematology Advisor - December 13th, 2020
- Venetoclax/Azacitidine Combination Efficacious for the Treatment of Older Patients With Higher-Risk Myelodysplastic Syndrome - Oncology Nurse Advisor - December 13th, 2020
- Rocket Pharmaceuticals Presents Positive Clinical Data from its Fanconi Anemia and Leukocyte Adhesion Deficiency-I Programs at the 62nd American... - December 13th, 2020
- Precigen Presents New Data Supporting the Safety, Clinical Activity, Expansion and Persistence of PRGN-3006 UltraCAR-T at the 62nd ASH Annual Meeting... - December 13th, 2020
- CLL patients in England to get AZ's Calquence after okay from NICE - - pharmaphorum - December 13th, 2020
- BeyondSpring Announces New Positive PROTECTIVE-2 Phase 3 Registrational Trial Results at the 2020 San Antonio Breast Cancer Symposium - BioSpace - December 10th, 2020
- Joliet 2-year-old gets pre-holiday gift: tests that show he's cancer-free - The Herald-News - December 10th, 2020
- BerGenBio Presents Updated Clinical Data From Two Phase II Studies Of Bemcentinib in AML and MDS Patients At Ash 2020 - PRNewswire - December 6th, 2020
- UCART22 Safe and Active in CD22-Expressing B-Cell ALLs - Targeted Oncology - December 6th, 2020
- Cancer center is a contributor to 49 research studies at the 62nd American Society of Hematology Annual Meeting - Newswise - December 5th, 2020
- Outlook on the Multiple Myeloma Drugs Global Market to 2025 - by Therapy, Drug Type, End-user, Distribution Channel and Region -... - December 5th, 2020
